Rh. Foster et Gl. Plosker, Glipizide - A review of the pharmacoeconomic implications of the extended-release formulation in Type 2 diabetes mellitus, PHARMACOECO, 18(3), 2000, pp. 289-306
Sources: Medical literature published in any language since 1983 on glipizi
de, identified using AdisBase (a proprietary database of Adis International
, Auckland, New Zealand) and Medline. Additional references were identified
from the reference lists of published articles. Bibliographical informatio
n, including contributory unpublished data, was also requested from the com
pany developing the drug.
Search strategy: AdisBase search terms were 'Glipizide' or 'Type-2-diabetes
-mellitus' and ('health-economics' or 'pharmacoepidemiology' or 'prescribin
g' or 'hospitalisation' or 'formularies' or 'drug-utilisation' or 'meta-ana
lysis' or 'therapeutic-substitution' or 'epidemiology'), or 'Glipizide' and
'Type-2-diabetes-mellitus'. Medline search terms were 'Glipizide' or 'Type
-2-diabetes-mellitus' and ('economics' or 'health-policy' or 'quality-of-li
fe' or 'models-statistical' or 'health-planning' or 'epidemiology' or 'guid
eline in pt' or 'practice-guidelines in pt'. Searches were last updated 01
August 2000.
Selection: Economic analyses in patients with type 2 diabetes mellitus who
received Glipizide Gastrointestinal Therapeutic System. Inclusion of studie
s was based mainly on the methods section of the trials. Relevant backgroun
d data on epidemiology and cost of illness are also included.